- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Patent holdings for IPC class C07D 401/02
Total number of patents in this class: 634
10-year publication summary
|
40
|
48
|
35
|
34
|
32
|
39
|
48
|
32
|
45
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2184 |
15 |
| Boehringer Ingelheim International GmbH | 4509 |
12 |
| AstraZeneca AB | 2832 |
11 |
| Medshine Discovery Inc. | 592 |
11 |
| Merck Sharp & Dohme LLC | 3729 |
10 |
| Bristol-myers Squibb Company | 4811 |
8 |
| Janssen Pharmaceutica N.V. | 3231 |
7 |
| Abbvie Inc. | 1842 |
7 |
| Vertex Pharmaceuticals Incorporated | 1597 |
7 |
| RespiVert Ltd. | 79 |
7 |
| Sunshine Lake Pharma Co., Ltd. | 618 |
7 |
| Epizyme, Inc. | 357 |
6 |
| MyoKardia, Inc. | 110 |
6 |
| Xizang Haisco Pharmaceutical Co., Ltd. | 129 |
6 |
| The Regents of the University of California | 20574 |
5 |
| Alcon, Inc. | 5719 |
5 |
| Angion Biomedica Corp. | 59 |
5 |
| Nanoquantum Sciences, Inc. | 6 |
5 |
| Regranion, LLC | 12 |
5 |
| Insilico Medicine IP Limited | 159 |
5 |
| Other owners | 484 |